Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BGB-58067 in Newly Diagnosed Glioblastoma
NCT07485049Phase 1Recruiting
- Sponsor
- Ivy Brain Tumor Center
- Start
- May 2026
- Primary completion
- Nov 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of BGB-58067 in glioblastoma (GBM) (2 arms), sponsored by Ivy Brain Tumor Center. Primary endpoints: Proportion of Participants with >= 50% Decrease from Baseline in SDMA Expression, or with SDMA H-Score <= 70 and Proportion of Participants Alive at 12 Months. Started May 2026; status: recruiting.
02
Drugs
BGB-58067
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on NCT07485049.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07485049.